Johnson & Johnson informs that your vacancy is effective against the COVID-19 of a single dose and which is preparing to apply to the Food and Drug Administration (FDA, for its seals in English) for authorization to use the weekly semesters.
If the authorities approve the vacancy, it can be estimated that it will be finalized in February, series the available third in the country, together with Pfizer-BioNTech and Modern.
Doctor Anthony Fauci, the country’s chief infectiologist, said he was very optimistic about the results of Johnson & Johnson’s studies. is a vaccine of a sole injection, in place of how they have been approved, and solo requires refrigerator simple.
“It’s barata and the company is capable of producing doses for miles of millions”, Fauci said at a press conference of the air force against the Casa Blanca pandemic.
The specialist added that the vaccine has a high efficacy to protect patients from severe infections. “In the studio, no hospitalizations or deaths in the group that received the vaccine”, indicated.
The results of the Phase 3 Johnson & Johnson trial, which unveiled the joint venture with Janssen Pharmaceuticals, found that the single dose was effective in a 72% for preventing infections as moderate as severe and 85% for severe cases, which includes those who require hospitalization. A moderate infection includes symptoms such as low oxygen levels, failure to breathe or deep vein thrombosis.
The studios are hicieron with 44,000 participants in the United States, South Africa and various countries of Latin America.
The effects vary according to the region. In Latin America, 66% of cases have been reported to be less effective. And in South Africa, a new contagious new species has been detected, at 57%.
[Novavax comunica que su vacuna contra el COVID-19 tiene un 89.3% de efectividad]
Without embargo, the vaccine will generally provide a high level of protection to prevent serious illness. “There is only one person who is vaccinated and has the infection after four weeks in a hospital,” said NBC News’ German cadet doctor Mathai Mammen, Johnson & Johnson’s director of worldwide investigations and development.
“I live to believe that this vaccine will ignite this pandemic,” said Mammen. Tampoco is registered secondary effects important, including allergic-graft reactions, such as anaphylaxis.
Aún así, the minor efficacy of the vaccine against the variant detected South Africa is preoccupying. The first cases of this mutation were detected in the United States.
More information on NBC News.